Perinatal outcomes of Australian buprenorphine-exposed mothers and their newborn infants

Journal of Paediatrics and Child Health

Volumn 49, Issue 9, 2013, Pages 746-753

  Patel, Pankaj ^a   Abdel Latif, Mohamed E ^f,g   Hazelton, Briony ^c   Wodak, Alex ^e   Chen, Julia ^a   Emsley, Fiona ^a   Feller, John M ^b   Lui, Kei ^a,d   Oei, Ju Lee ^a,d  

^a ROYAL HOSPITAL FOR WOMEN   (Australia)

^b SYDNEY CHILDREN'S HOSPITAL   (Australia)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

^f Centenary Hospital for Women and Children   (Australia)

^g AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

buprenorphine; neonatal abstinence syndrome; pregnancy

Indexed keywords

AMPHETAMINE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; CANNABINOID; CENTRAL STIMULANT AGENT; CODEINE; DIAMORPHINE; METHADONE; MORPHINE; OPIATE;

ABSTINENCE; ARTICLE; AUSTRALIA; CONTROLLED STUDY; DRUG SAFETY; FETUS OUTCOME; HIGH BIRTH WEIGHT; HOME CARE; HUMAN; LENGTH OF STAY; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; NEWBORN; OPIATE ADDICTION; OUTCOME ASSESSMENT; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; SIDE EFFECT; WITHDRAWAL SYNDROME;

BUPRENORPHINE; NEONATAL ABSTINENCE SYNDROME; PREGNANCY;

ADULT; ANALGESICS, OPIOID; AUSTRALIAN CAPITAL TERRITORY; BUPRENORPHINE; FEMALE; HUMANS; INFANT, NEWBORN; MEDICAL AUDIT; MORPHINE; NEONATAL ABSTINENCE SYNDROME; NEW SOUTH WALES; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84883758562     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/jpc.12264     Document Type: Article

References (27)

1. Abdel-Latif ME, Bajuk B, Lui K, et al.; NSW on ACT Neonatal Intensive Care Units' Study (NICUS) Group. Short-term outcomes of infants of substance-using mothers admitted to neonatal intensive care units in New South Wales and the Australian Capital Territory. J. Paediatr. Child Health 2007; 43: 127-133.
2. Australian Institute of Health and Welfare. Statistics on drug use in Australia 2006. In. No. 18 ed. Canberra: Australian Institute of Health and Welfare, 2007.
3. Belcheva MM, Bohn LM, Ho MT, et al. Brain opioid receptor adaptation and expression after prenatal exposure to buprenorphine. Brain Res. Dev. Brain Res. 1998; 111: 35-42.
4. Black M, Schuler M, Nair P,. Prenatal drug exposure: neurodevelopmental outcome and parenting environment. J. Pediatr. Psychol. 1993; 18: 605-620.
5. Wallace C, Burns L, Gilmour S, et al. Substance use, psychological distress and violence among pregnant and breastfeeding Australian women. Aust. N. Z. J. Public Health 2007; 31: 51-56.
6. Oei JL, Abdel-Latif ME, Craig F, et al.; NSW and ACT NAS Epidemiology Group. Short-term outcomes of mothers and newborn infants with comorbid psychiatric disorders and drug dependency. Aust. N. Z. J. Psychiatry 2009; 43: 323-331.
7. Finnegan LP, Kron RE, Connaughton JF, et al. Neonatal abstinence syndrome: assessment and management. Addict. Dis. 1975; 2: 141-158.
8. Kahila H, Saisto T, Kivitie-Kallio S, et al. A prospective study on buprenorphine use during pregnancy: effects on maternal and neonatal outcome. Acta Obstet. Gynecol. Scand. 2007; 86: 185-190.
9. Hulse GK, Milne E, English DR, et al. The relationship between maternal use of heroin and methadone and infant birth weight. Addiction 1997; 92: 1571-1579.
10. Lacroix I, Berrebi A, Garipuy D, et al. Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. Eur. J. Clin. Pharmacol. 2011; 67: 1053-1059.
11. Oei J, Lui K,. Management of the newborn infant affected by maternal opiates and other drugs of dependency. J. Paediatr. Child Health 2007; 43: 9-18.
12. Downing JW, Leary WP, White ES,. Buprenorphine: a new potent long-acting synthetic analgesic. Comparison with morphine. Br. J. Anaesth. 1977; 49: 251-255.
13. Jernite M, Viville B, Escande B, et al. Buprenorphine and pregnancy. Analysis of 24 cases. Arch. Pediatr. 1999; 6: 1179-1185.
14. Lejeune C, Aubisson S, Simmat-Durand L, et al.; Groupe d'Etudes Grossesse et addictions. Withdrawal syndromes of newborns of pregnant drug abusers maintained under methadone or high-dose buprenorphine: 246 cases. Ann. Med. Interne (Paris) 2001; 152 (Suppl. 7): 21-27.
15. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N. Engl. J. Med. 2010; 363: 2320-2331.
16. World Health Organization. Proposal for the Inclusion of Buprenorphine in the WHO Model List of Essential Medicines. Department of Mental Health and Substance Abuse, October 2004. Available from: http://www.who.int/substance- abuse/activities/%20buprenorphine-essential-medicines.pdf. [accessed 13 November 2011].
17. Abdel-Latif ME, Oei J, Craig F, Lui K, NSW and ACT NAS Epidemiology Group. Profile of infants born to drug-using mothers: a state-wide audit. J. Paediatr. Child Health 2013; 49: E80-86.
18. Burns L, Mattick RP,. Using population data to examine the prevalence and correlates of neonatal abstinence syndrome. Drug Alcohol Rev. 2007; 26: 487-492.
19. Concheiro M, Jones HE, Johnson RE, et al. Maternal buprenorphine dose, placenta buprenorphine, and metabolite concentrations and neonatal outcomes. Ther. Drug Monit. 2010; 32: 206-215.
20. Ilett KF, Hackett LP, Gower S, et al. Estimated dose exposure of the neonate to buprenorphine and its metabolite norbuprenorphine via breastmilk during maternal buprenorphine substitution treatment. Breastfeed. Med. 2012; 7: 269-274.
21. Bazazi AR, Yokell M, Fu JJ, et al. Illicit use of buprenorphine-/naloxone among injecting and non-injecting opioid users. J. Addict. Med. 2011; 5: 175-180.
22. New South Wales Health. Neonatal Abstinence Syndrome Guidelines, 2005. Available from: http://www0.health.nsw.gov.au/policies/pd/%202005/PD2005-494. html [accessed 12 November 2011].
23. Smith AA, Hui FW, Crofford MJ,. Inhibition of growth in young mice treated with d,1-methadone. Eur. J. Pharmacol. 1977; 43: 307-314.
24. Jansson LM, Dipietro JA, Velez M, et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicol. Teratol. 2011; 33: 240-243.
25. Lipsitz PJ,. A proposed narcotic withdrawal score for use with newborn infants. A pragmatic evaluation of its efficacy. Clin. Pediatr. (Phila) 1975; 14: 592-594.
26. Abdel-Latif ME, Pinner J, Clews S, et al. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics 2006; 117: e1163-1169.
27. Minozzi S, Amato L, Vecchi S, et al. Maintenance agonist treatments for opiate dependent pregnant women. Cochrane Database Syst. Rev. [Internet] 2008; (2): CD006318. Available from: http://onlinelibrary.wiley.com/doi/10.1002/ 14651858.CD006318.pub2/full [accessed 12 November 2011]